Join online as an expert panel presents their selection of transformational clinical data from the EADV 2026 Annual Congress and discusses the impacts for practice.

An updated international consensus on type 2 diabetes management has broadened the focus from glycaemic control alone to the prevention of long-term complications with the help of emerging therapies.

ADHD and autism is particularly prevalent among young people diagnosed with type 2 diabetes before the age of 20, according to data presented at the EASD annual meeting. The analysis used TriNetX US ...

US hepatologists have backed carvedilol or variceal ligation for the treatment of high-risk esophageal varices and endorsed an increased focus on vaccinations for patients with cirrhosis as part of a ...

More than one thousand delegates are expected to converge on Auckland’s new conference centre for a highly-anticipated Blood 2026, with a scientific program showcasing the latest innovations across ...

Triple agonist therapy retatrutide delivers mean weight reductions of more than 20% at the highest dose for patients with type 2 diabetes, results presented at the European Association for the Study ...

Oncologists who receive payments from drug manufacturers are more likely to prescribe the company’s promoted cancer treatment, regardless of whether the treatment fits the relevant clinical guideline, ...

Lowering B-cell burden and systemic inflammation may reduce the risk of cytokine release syndrome (CRS) following CAR T-cell therapy in patients with autoimmune disease, new research suggests. The ...

Prediabetes combined with subclinical myocardial injury or stress signals a tenfold higher risk of heart failure in hypertensive adults, a large US study has found. The study of 8,234 adults with ...

Novartis has suspended multiple trials evaluating its CAR-T therapy for autoimmune diseases following serious inflammatory side effects. The pause affects trials of rapcabtagene autoleucel (rap-cel) ...

Watch again as an expert panel shares the latest clinical evidence on current treatment and management strategies for paroxysmal nocturnal haemoglobinuria, focusing on frontline and second-line care.